FDA regulators recently released a preliminary report that suggests they will soon approve the salmon-hybrid 'AquAdvantage fish,' which was developed in the laboratories of AquaBounty.
The FDA must wait two months before making their final decision, but so far they have said that the genetically-engineered animal is safe to be sold, reports the Associated Press.
The AquAdvantage fish, a hybrid of the Pacific Chinook salmon and an eelpout, is genetically engineered to grow twice as big as a normal salmon.
The FDA wrote: “In all other respects, the AquAdvantage fish is identical to other Atlantic salmon" and "will not have any significant impacts on the quality of the human environment of the United States."
The FDA has 60 days to hear remarks from the public before it makes a final decision.
Bill Freese, a science policy analyst with the Center for Food Safety, told Women’s Health Magazine that the FDA has “a very lax regulatory system."
Freese added: “This is a radical new technology. We need very good, careful, close regulation, and we just don't have that. We can't be assured of the safety of any of these genetically engineered organisms."
Developing the AquAdvantage fish has cost AquaBounty nearly two decades of research and tens of millions of dollars.